Skip to main content
. 2014 May 9;30(11):1085–1102. doi: 10.1002/cnm.2645

Figure 6.

Figure 6

Model simulations of the variation in normalised receptor activator of nuclear factor kappa-B ligand (RANKL) and interleukin-6 (IL-6) concentrations with respect to their initial values (multiple myeloma cells are injected at day 201 and removed at day 1001).